OncoHist Technology-Based Candidates

Internal Pipeline

Preclinical Phase 1 Phase 2 Phase 3
OncoHist™ OncoHist Acute Myeloid Leukemia
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
  • Indicates programs completed.
  • Indicates programs in progress in such phase.

Collaborative Partner Programs

Preclinical Phase 1 Phase 2 Phase 3 Partners
OncoHist™ OncoHist AML
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
SynBio
NHL
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
SynBio
  • Indicates programs completed.
  • Indicates programs in progress in such phase.

OncoHist™ for AML

OncoHist™ is currently being evaluated in a Phase 1/2 trial for the treatment of Acute Myeloid Leukemia (AML) in refractory patients. This study, testing OncoHist as a combination therapy together with Cytarabine, is being developed with our Russian partner, Pharmsynthez. The trial has now been expanded to include additional patients in a multicenter recruitment strategy.

OncoHist™ for NHL

OncoHist™ is also being evaluated in a separate Phase 1/2 trial for refractory Non-Hodgkin Lymphoma (NHL). This trial, undertaken together with our partner SynBio LLC, is a dose escalation study designed to assess the safety, pharmacokinetics and efficacy of OncoHist in adult patients unresponsive to standard treatment.

OncoHist™ for AML: US initiative

Another OncoHist initiative is currently underway, focused on defining the clinical program with the aim of initiating a Phase 1/2 trial in the United States. We have also initiated an important partnership with the Dana Farber Cancer Institute (DFCI) to evaluate OncoHist's effect on patient cells found resistant to treatment by other chemotherapeutics. OncoHist is undergoing the NCI 60 screening evaluation at the U.S. National Cancer institute.